DOCSLIB.ORG

Novel Mutations in the CHST6 Gene Associated with Macular Corneal Dystrophy in Southern India

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Mutations in the CHST6 Gene Associated with Macular Corneal Dystrophy in Southern India OPHTHALMIC MOLECULAR GENETICS SECTION EDITOR: EDWIN M. STONE, MD, PhD Novel Mutations in the CHST6 Gene Associated With Macular Corneal Dystrophy in Southern India John F. Warren, MD; Anthony J. Aldave, MD; M. Srinivasan, MD; Eugene J. Thonar, PhD; Abha B. Kumar, MD; Vicky Cevallos, BS; John P. Whitcher, MD, MPH; Todd P. Margolis, MD, PhD Objective: To further characterize the role of the car- Glu274Lys), 2 compound heterozygous missense muta- bohydrate sulfotransferase (CHST6) gene in macular cor- tions (Arg93His and Ala206Thr), 5 homozygous dele- neal dystrophy (MCD) through identification of caus- tion mutations (delCG707-708, delC890, delA1237, ative mutations in a cohort of affected patients from del1748-1770, and delORF), and 2 homozygous replace- southern India. ment mutations (ACCTAC 1273 GGT, and GCG 1304 AT). One patient with type II MCD was heterozygous for Methods: Genomic DNA was extracted from buccal epi- the C890 deletion mutation, whereas 4 possessed no thelium of 75 patients (51 families) with MCD, 33 un- CHST6 coding region mutations. affected relatives, and 48 healthy volunteers. The cod- ing region of the CHST6 gene was evaluated by means Conclusion: A variety of previously unreported muta- of polymerase chain reaction amplification and direct se- tions in the coding region of the CHST6 gene are associ- quencing. Subtyping of MCD into types I and II was per- ated with type I MCD in a cohort of patients in southern formed by measuring serum levels of antigenic keratan India. sulfate. Clinical Relevance: An improved understanding of Results: Seventy patients were classified as having type the genetic basis of MCD allows for earlier, more accu- I MCD, and 5 patients as having type II MCD. Analysis rate diagnosis of affected individuals, and may provide of the CHST6 coding region in patients with type I MCD the foundation for the development of novel disease identified 11 homozygous missense mutations (Leu22Arg, treatments. His42Tyr, Arg50Cys, Arg50Leu, Ser53Leu, Arg97Pro, Cys102Tyr, Arg127Cys, Arg205Gln, His249Pro, and Arch Ophthalmol. 2003;121:1608-1612 ACULAR CORNEAL dys- the basis of analysis of antigenic KS trophy (MCD) is an (AgKS) levels in serum and immunohis- autosomal recessive tochemical evaluation of corneal buttons disorder of corneal obtained at the time of penetrating kera- keratan sulfate (KS) toplasty. Affected patients with unde- From the Francis I. Proctor metabolism that is characterized by bilat- tectable serum levels of AgKS are classi- M 1-4 Foundation and the Department eral progressive corneal clouding. A su- fied as having type I MCD, whereas those of Ophthalmology, University perficial stromal haze develops in the first with low or reference levels are classified of California–San Francisco to second decade of life, and is followed as having type II MCD.5 Type IA MCD is (Drs Warren, Aldave, Kumar, Whitcher, and Margolis and by an accumulation of irregular, focal, distinguished from type I MCD by the Ms Cevallos); the Cornea and gray-white corneal stromal deposits. These presence or absence, respectively, of External Disease Service, deposits involve the anterior corneal highly sulfated AgKS within corneal Aravind Eye Hospital, Madurai, stroma centrally and the deep stroma pe- keratocytes in individuals who have no India (Dr Srinivasan); and the ripherally. Affected patients typically ex- detectable amounts of this form of AgKS Departments of Biochemistry, perience an early-onset, progressive de- in serum.6,7 Orthopedic Surgery, and cline in vision, often leading to penetrating Recently, investigators have linked Internal Medicine, Rush keratoplasty. Histopathologic findings in MCD to mutations in a newly recognized Medical College, Chicago, Ill MCD demonstrate abnormal accumula- carbohydrate sulfotransferase gene (Dr Thonar). Dr Aldave is now 8 with the Jules Stein Eye tions of glycosaminoglycans in the extra- (CHST6) on chromosome 16 (16q22). Institute, University of cellular stroma, keratocytes, and endothe- The CHST6 gene product, corneal California–Los Angeles. The lial cells. N-acetylglucosamine-6-sulfotransferase authors have no relevant Macular corneal dystrophy is com- (C-GlcNac6ST), is thought to be impor- financial interest in this article. monly divided into types I, IA, and II, on tant in producing sulfated KS, the pre- (REPRINTED) ARCH OPHTHALMOL / VOL 121, NOV 2003 WWW.ARCHOPHTHALMOL.COM 1608 ©2003 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 netic analysis was performed. In addition, a portion of serum from each blood sample was sent to Rush Medical College, Chi- cago, Ill, for quantification of AgKS levels in serum. DNA PREPARATION After receiving informed consent from each study participant, a blood sample and buccal epithelial swab were obtained. Ap- proximately 3 mL of peripheral blood was drawn from each sub- ject by means of standard phlebotomy. In addition, samples of buccal mucosal epithelium were obtained by twirling a cytol- ogy brush (CytoSoft brush CP-5B; Medical Packaging Corpo- ration, Camarillo, Calif) vigorously against the buccal epithe- lium. Genomic DNA was prepared from the buccal epithelial cells and/or blood leukocytes using a spin protocol (QIAamp DNA Mini Kit; Qiagen Inc, Valencia, Calif). POLYMERASE CHAIN REACTION AMPLIFICATION The CHST6 coding region was amplified by means of polymer- Slit-beam photograph of a representative study subject. Sclerotic scatter ase chain reaction (PCR) using primers designed to create demonstrates the highly characteristic, diffusely distributed, irregular, focal, gray-white corneal stromal deposits of macular corneal dystrophy. 3 overlapping amplicons. The oligonucleotide primers used were identical to those reported by Akama et al,8 with the exception of the middle coding region reverse primer (5Ј-TCCGTGGGTGATGTTATGGAT-3Ј). Each reaction was dominant glycosaminoglycan expressed in the adult cor- performed in a 50-µL mixture containing 25 µL of PCR pre- nea. Lack of activity of this enzyme is thought to result mix (100mM Tris hydrochloride [pH, 8.3], 100mM potas- in the production of unsulfated KS, leading to a loss of sium chloride, 400µM of each deoxynucleotide phosphate, and transparency in the corneas of affected patients. Muta- proprietary concentrations of magnesium chloride and PCR en- tions within the coding region of CHST6 have been found hancer) (FailSafe PCR 2ϫPreMix D; Epicentre, Madison, Wis), to be associated with type I MCD, whereas deletions and 0.2µM of each primer, 1.5 U of DNA polymerase (AmpliTaq; rearrangements in the upstream regulatory region have (Applied Biosystems, Foster City, Calif), and approximately 100 been identified in patients with type II MCD. Despite the ng of genomic DNA. Thermal cycling was performed with variety of mutations reported, all of the gene defects are the following program: initial denaturation for 3 minutes at associated with a common disease phenotype.8-11 96°C, 35 cycles of 96°C for 30 seconds, 57°C for 30 seconds, and 72°C for 45 seconds, and final extension for 5 minutes at In this study, we sought to further characterize the 72°C (GeneAmp PCR System 9700; Applied Biosystems). role of the CHST6 gene in MCD through the identifica- tion of causative mutations in a large cohort of affected DNA SEQUENCING patients in southern India. The relatively high preva- lence of MCD in southern India is probably a result of Amplified DNA was column purified (QIAquick PCR purifi- the high frequency of consanguineous marriage within cation kit; Qiagen Inc) and sequenced directly according to the this population. Because many patients with MCD have protocols accompanying the cycle sequencing kit (BigDye Ter- been carefully followed up for years at the Aravind Eye minator kit; Applied Biosystems). A genetic analyzer (ABI Prism Hospital (AEH), Madurai, India, we were able to enroll 310; Applied Biosystems) was used to collect and analyze the a large series of patients to undergo molecular genetic sequence data. Nucleotide sequences were compared with the published CHST6 complementary DNA sequence. analysis. METHODS AgKS QUANTIFICATION After study approval was obtained from the institutional re- An epitope present on long KS chains was quantified using a view board at the AEH and the University of California–San well-characterized enzyme-linked immunosorbent assay that 12-14 Francisco (H7177-18489-01), a computerized medical record uses the 1/20/5-D-4 monoclonal antibody. Levels of AgKS search was performed to identify all patients with MCD seen in serum are reported here as equivalents of a standard of AgKS 12-14 at AEH between January 1, 1990, and January 1, 2000. The di- highly purified from human costal cartilage. agnosis of MCD was based on the distinctive clinical features (Figure), and in most cases was confirmed by results of his- topathologic examination of the excised corneal buttons. All RESULTS cases were consistent with an autosomal recessive inheritance pattern. Families with affected patients older than 20 years were A total of 75 affected patients, representing 51 different contacted by telephone or letter and asked to participate in the families, were enrolled in the study. On the basis of un- study. Unrelated, unaffected, healthy volunteers were re- detectable levels of serum AgKS, 70 of the affected pa- cruited to serve as control subjects. All study subjects re- turned to AEH for slitlamp examination and collection of blood tients (47 families) were classified as having type I MCD. samples and buccal mucosal swabs. Family members were con- The other 5 affected patients (4 families) had serum lev- sidered unaffected if they were older than 20 years and with- els of AgKS that were low or within the reference range out clinical evidence of MCD. All samples were transported to (103-210 ng/mL) and were classified as having type II University of California–San Francisco, where molecular ge- MCD. Levels of AgKS within the reference range were (REPRINTED) ARCH OPHTHALMOL / VOL 121, NOV 2003 WWW.ARCHOPHTHALMOL.COM 1609 ©2003 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 Table 1.
Load more

Recommended publications
  • Seq2pathway Vignette
    seq2pathway Vignette Bin Wang, Xinan Holly Yang, Arjun Kinstlick May 19, 2021 Contents 1 Abstract 1 2 Package Installation 2 3 runseq2pathway 2 4 Two main functions 3 4.1 seq2gene . .3 4.1.1 seq2gene flowchart . .3 4.1.2 runseq2gene inputs/parameters . .5 4.1.3 runseq2gene outputs . .8 4.2 gene2pathway . 10 4.2.1 gene2pathway flowchart . 11 4.2.2 gene2pathway test inputs/parameters . 11 4.2.3 gene2pathway test outputs . 12 5 Examples 13 5.1 ChIP-seq data analysis . 13 5.1.1 Map ChIP-seq enriched peaks to genes using runseq2gene .................... 13 5.1.2 Discover enriched GO terms using gene2pathway_test with gene scores . 15 5.1.3 Discover enriched GO terms using Fisher's Exact test without gene scores . 17 5.1.4 Add description for genes . 20 5.2 RNA-seq data analysis . 20 6 R environment session 23 1 Abstract Seq2pathway is a novel computational tool to analyze functional gene-sets (including signaling pathways) using variable next-generation sequencing data[1]. Integral to this tool are the \seq2gene" and \gene2pathway" components in series that infer a quantitative pathway-level profile for each sample. The seq2gene function assigns phenotype-associated significance of genomic regions to gene-level scores, where the significance could be p-values of SNPs or point mutations, protein-binding affinity, or transcriptional expression level. The seq2gene function has the feasibility to assign non-exon regions to a range of neighboring genes besides the nearest one, thus facilitating the study of functional non-coding elements[2]. Then the gene2pathway summarizes gene-level measurements to pathway-level scores, comparing the quantity of significance for gene members within a pathway with those outside a pathway.
    [Show full text]
  • Investigating the Genetic Basis of Cisplatin-Induced Ototoxicity in Adult South African Patients
    --------------------------------------------------------------------------- Investigating the genetic basis of cisplatin-induced ototoxicity in adult South African patients --------------------------------------------------------------------------- by Timothy Francis Spracklen SPRTIM002 SUBMITTED TO THE UNIVERSITY OF CAPE TOWN In fulfilment of the requirements for the degree MSc(Med) Faculty of Health Sciences UNIVERSITY OF CAPE TOWN University18 December of Cape 2015 Town Supervisor: Prof. Rajkumar S Ramesar Co-supervisor: Ms A Alvera Vorster Division of Human Genetics, Department of Pathology, University of Cape Town 1 The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non- commercial research purposes only. Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author. University of Cape Town Declaration I, Timothy Spracklen, hereby declare that the work on which this dissertation/thesis is based is my original work (except where acknowledgements indicate otherwise) and that neither the whole work nor any part of it has been, is being, or is to be submitted for another degree in this or any other university. I empower the university to reproduce for the purpose of research either the whole or any portion of the contents in any manner whatsoever. Signature: Date: 18 December 2015 ' 2 Contents Abbreviations ………………………………………………………………………………….. 1 List of figures …………………………………………………………………………………... 6 List of tables ………………………………………………………………………………….... 7 Abstract ………………………………………………………………………………………… 10 1. Introduction …………………………………………………………………………………. 11 1.1 Cancer …………………………………………………………………………….. 11 1.2 Adverse drug reactions ………………………………………………………….. 12 1.3 Cisplatin …………………………………………………………………………… 12 1.3.1 Cisplatin’s mechanism of action ……………………………………………… 13 1.3.2 Adverse reactions to cisplatin therapy ……………………………………….
    [Show full text]
  • 1 Mutational Heterogeneity in Cancer Akash Kumar a Dissertation
    Mutational Heterogeneity in Cancer Akash Kumar A dissertation Submitted in partial fulfillment of requirements for the degree of Doctor of Philosophy University of Washington 2014 June 5 Reading Committee: Jay Shendure Pete Nelson Mary Claire King Program Authorized to Offer Degree: Genome Sciences 1 University of Washington ABSTRACT Mutational Heterogeneity in Cancer Akash Kumar Chair of the Supervisory Committee: Associate Professor Jay Shendure Department of Genome Sciences Somatic mutation plays a key role in the formation and progression of cancer. Differences in mutation patterns likely explain much of the heterogeneity seen in prognosis and treatment response among patients. Recent advances in massively parallel sequencing have greatly expanded our capability to investigate somatic mutation. Genomic profiling of tumor biopsies could guide the administration of targeted therapeutics on the basis of the tumor’s collection of mutations. Central to the success of this approach is the general applicability of targeted therapies to a patient’s entire tumor burden. This requires a better understanding of the genomic heterogeneity present both within individual tumors (intratumoral) and amongst tumors from the same patient (intrapatient). My dissertation is broadly organized around investigating mutational heterogeneity in cancer. Three projects are discussed in detail: analysis of (1) interpatient and (2) intrapatient heterogeneity in men with disseminated prostate cancer, and (3) investigation of regional intratumoral heterogeneity in
    [Show full text]
  • (P -Value<0.05, Fold Change≥1.4), 4 Vs. 0 Gy Irradiation
    Table S1: Significant differentially expressed genes (P -Value<0.05, Fold Change≥1.4), 4 vs. 0 Gy irradiation Genbank Fold Change P -Value Gene Symbol Description Accession Q9F8M7_CARHY (Q9F8M7) DTDP-glucose 4,6-dehydratase (Fragment), partial (9%) 6.70 0.017399678 THC2699065 [THC2719287] 5.53 0.003379195 BC013657 BC013657 Homo sapiens cDNA clone IMAGE:4152983, partial cds. [BC013657] 5.10 0.024641735 THC2750781 Ciliary dynein heavy chain 5 (Axonemal beta dynein heavy chain 5) (HL1). 4.07 0.04353262 DNAH5 [Source:Uniprot/SWISSPROT;Acc:Q8TE73] [ENST00000382416] 3.81 0.002855909 NM_145263 SPATA18 Homo sapiens spermatogenesis associated 18 homolog (rat) (SPATA18), mRNA [NM_145263] AA418814 zw01a02.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:767978 3', 3.69 0.03203913 AA418814 AA418814 mRNA sequence [AA418814] AL356953 leucine-rich repeat-containing G protein-coupled receptor 6 {Homo sapiens} (exp=0; 3.63 0.0277936 THC2705989 wgp=1; cg=0), partial (4%) [THC2752981] AA484677 ne64a07.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone IMAGE:909012, mRNA 3.63 0.027098073 AA484677 AA484677 sequence [AA484677] oe06h09.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone IMAGE:1385153, mRNA sequence 3.48 0.04468495 AA837799 AA837799 [AA837799] Homo sapiens hypothetical protein LOC340109, mRNA (cDNA clone IMAGE:5578073), partial 3.27 0.031178378 BC039509 LOC643401 cds. [BC039509] Homo sapiens Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 1, mRNA 3.24 0.022156298 NM_000043 FAS [NM_000043] 3.20 0.021043295 A_32_P125056 BF803942 CM2-CI0135-021100-477-g08 CI0135 Homo sapiens cDNA, mRNA sequence 3.04 0.043389246 BF803942 BF803942 [BF803942] 3.03 0.002430239 NM_015920 RPS27L Homo sapiens ribosomal protein S27-like (RPS27L), mRNA [NM_015920] Homo sapiens tumor necrosis factor receptor superfamily, member 10c, decoy without an 2.98 0.021202829 NM_003841 TNFRSF10C intracellular domain (TNFRSF10C), mRNA [NM_003841] 2.97 0.03243901 AB002384 C6orf32 Homo sapiens mRNA for KIAA0386 gene, partial cds.
    [Show full text]
  • Exome Sequencing in Sporadic Autism Spectrum Disorders Identifies Severe De Novo Mutations
    LETTERS Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations Brian J O’Roak1, Pelagia Deriziotis2, Choli Lee1, Laura Vives1, Jerrod J Schwartz1, Santhosh Girirajan1, Emre Karakoc1, Alexandra P MacKenzie1, Sarah B Ng1, Carl Baker1, Mark J Rieder1, Deborah A Nickerson1, Raphael Bernier3, Simon E Fisher2,4, Jay Shendure1 & Evan E Eichler1,5 Evidence for the etiology of autism spectrum disorders (ASDs) In contrast with array­based analysis of large de novo copy number has consistently pointed to a strong genetic component variants (CNVs), this approach has greater potential to implicate complicated by substantial locus heterogeneity1,2. We single genes in ASDs. sequenced the exomes of 20 individuals with sporadic ASD We selected 20 trios with an idiopathic ASD, each consistent with a (cases) and their parents, reasoning that these families sporadic ASD based on clinical evaluations (Supplementary Table 1), would be enriched for de novo mutations of major effect. pedigree structure, familial phenotypic evaluation, family history We identified 21 de novo mutations, 11 of which were and/or elevated parental age. Each family was initially screened by protein altering. Protein-altering mutations were significantly array comparative genomic hybridization (CGH) using a customized enriched for changes at highly conserved residues. We microarray9. We identified no large (>250 kb) de novo CNVs but did identified potentially causative de novo events in 4 out of identify a maternally inherited deletion (~350 kb) at 15q11.2 in one 20 probands, particularly among more severely affected family (Supplementary Fig. 1). This deletion has been associated individuals, in FOXP1, GRIN2B, SCN1A and LAMC3.
    [Show full text]
  • Ejhg2009157.Pdf
    European Journal of Human Genetics (2010) 18, 342–347 & 2010 Macmillan Publishers Limited All rights reserved 1018-4813/10 $32.00 www.nature.com/ejhg ARTICLE Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjects Zari Dastani1,2,Pa¨ivi Pajukanta3, Michel Marcil1, Nicholas Rudzicz4, Isabelle Ruel1, Swneke D Bailey2, Jenny C Lee3, Mathieu Lemire5,9, Janet Faith5, Jill Platko6,10, John Rioux6,11, Thomas J Hudson2,5,7,9, Daniel Gaudet8, James C Engert*,2,7, Jacques Genest1,2,7 Low levels of high-density lipoprotein cholesterol (HDL-C) are an independent risk factor for cardiovascular disease. To identify novel genetic variants that contribute to HDL-C, we performed genome-wide scans and quantitative association studies in two study samples: a Quebec-wide study consisting of 11 multigenerational families and a study of 61 families from the Saguenay– Lac St-Jean (SLSJ) region of Quebec. The heritability of HDL-C in these study samples was 0.73 and 0.49, respectively. Variance components linkage methods identified a LOD score of 2.61 at 98 cM near the marker D16S515 in Quebec-wide families and an LOD score of 2.96 at 86 cM near the marker D16S2624 in SLSJ families. In the Quebec-wide sample, four families showed segregation over a 25.5-cM (18 Mb) region, which was further reduced to 6.6 Mb with additional markers. The coding regions of all genes within this region were sequenced. A missense variant in CHST6 segregated in four families and, with additional families, we observed a P value of 0.015 for this variant.
    [Show full text]
  • Downloaded from Here
    bioRxiv preprint doi: https://doi.org/10.1101/017566; this version posted November 19, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 1 Testing for ancient selection using cross-population allele 2 frequency differentiation 1;∗ 3 Fernando Racimo 4 1 Department of Integrative Biology, University of California, Berkeley, CA, USA 5 ∗ E-mail: [email protected] 6 1 Abstract 7 A powerful way to detect selection in a population is by modeling local allele frequency changes in a 8 particular region of the genome under scenarios of selection and neutrality, and finding which model is 9 most compatible with the data. Chen et al. [2010] developed a composite likelihood method called XP- 10 CLR that uses an outgroup population to detect departures from neutrality which could be compatible 11 with hard or soft sweeps, at linked sites near a beneficial allele. However, this method is most sensitive 12 to recent selection and may miss selective events that happened a long time ago. To overcome this, 13 we developed an extension of XP-CLR that jointly models the behavior of a selected allele in a three- 14 population tree. Our method - called 3P-CLR - outperforms XP-CLR when testing for selection that 15 occurred before two populations split from each other, and can distinguish between those events and 16 events that occurred specifically in each of the populations after the split.
    [Show full text]
  • A Comprehensive Evaluation of 181 Reported CHST6 Variants in Patients with Macular Corneal Dystrophy
    www.aging‐us.com AGING 2019, Vol. 11, No. 3 Research Paper A comprehensive evaluation of 181 reported CHST6 variants in patients with macular corneal dystrophy Jing Zhang1, Dan Wu1, Yue Li1, Yidan Fan1, Yiqin Dai1, Jianjiang Xu1 1Department of Ophthalmology and Visual Science, Eye and ENT Hospital, Shanghai Medical College of Fudan University, NHC Key Laboratory of Myopia (Fudan University), Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, China Correspondence to: Jianjiang Xu; email: [email protected] Keywords: CHST6, macular corneal dystrophy, genetic variants Received: October 23, 2018 Accepted: January 25, 2019 Published: February 4, 2019 Copyright: Zhang et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Macular corneal dystrophy (MCD) is an autosomal recessive disease featured by bilateral progressive stromal clouding and loss of vision, consequently necessitating corneal transplantation. Variants in CHST6 gene have been recognized as the most critical genetic components in MCD. Although many CHST6 variants have been described until now, the detailed mechanisms underlying MCD are still far from understood. In this study, we integrated all the reported CHST6 variants described in 408 MCD cases, and performed a comprehensive evaluation to better illustrate the causality of these variants. The results showed that majority of these variants (165 out of 181) could be classified as pathogenic or likely pathogenic. Interestingly, we also identified several disease causal variants with ethnic specificity. In addition, the results underscored the strong correlation between mutant frequency and residue conservation in the general population (Spearman’s correlation coefficient = ‐0.311, P = 1.20E‐05), thus providing potential candidate targets for further genetic manipulation.
    [Show full text]
  • Microarray Bioinformatics and Its Applications to Clinical Research
    Microarray Bioinformatics and Its Applications to Clinical Research A dissertation presented to the School of Electrical and Information Engineering of the University of Sydney in fulfillment of the requirements for the degree of Doctor of Philosophy i JLI ··_L - -> ...·. ...,. by Ilene Y. Chen Acknowledgment This thesis owes its existence to the mercy, support and inspiration of many people. In the first place, having suffering from adult-onset asthma, interstitial cystitis and cold agglutinin disease, I would like to express my deepest sense of appreciation and gratitude to Professors Hong Yan and David Levy for harbouring me these last three years and providing me a place at the University of Sydney to pursue a very meaningful course of research. I am also indebted to Dr. Craig Jin, who has been a source of enthusiasm and encouragement on my research over many years. In the second place, for contexts concerning biological and medical aspects covered in this thesis, I am very indebted to Dr. Ling-Hong Tseng, Dr. Shian-Sehn Shie, Dr. Wen-Hung Chung and Professor Chyi-Long Lee at Change Gung Memorial Hospital and University of Chang Gung School of Medicine (Taoyuan, Taiwan) as well as Professor Keith Lloyd at University of Alabama School of Medicine (AL, USA). All of them have contributed substantially to this work. In the third place, I would like to thank Mrs. Inge Rogers and Mr. William Ballinger for their helpful comments and suggestions for the writing of my papers and thesis. In the fourth place, I would like to thank my swim coach, Hirota Homma.
    [Show full text]
  • A Second Generation Human Haplotype Map of Over 3.1 Million Snps the International Hapmap Consortium1
    doi: 10.1038/nature06258 SUPPLEMENTARY INFORMATION A second generation human haplotype map of over 3.1 million SNPs The International HapMap Consortium1 Supplementary material S1 The density of common SNPs in the Phase II HapMap and the assembled human genome S2 Analysis of data quality S2.1 Analysis of amplicon structure to genotyping error S2.2 Analysis of genotype discordance from overlap with Seattle SNPs S2.3 Analysis of genotype discordance from fosmid end sequences S2.4 Analysis of monomorphism/polymorphism discrepancies S2.5 Interchromosomal LD S3. Analysis of population stratification S4. Analysis of relatedness S5. Segmental analysis of relatedness S6. Analysis of homozygosity S7. Perlegen genotyping protocols Supplementary tables Legends to supplementary figures 1 See end of manuscript for Consortium details www.nature.com/nature 1 doi: 10.1038/nature06258 SUPPLEMENTARY INFORMATION Supplementary text 1. The density of common SNPs in the Phase II HapMap and the assembled human genome. To estimate the fraction of all common variants on the autosomes that have been successfully genotyped in the consensus Phase II HapMap we note that in YRI (release 21) there are 2,334,980 SNPs with MAF≥0.05. Across the autosomes, the completed reference sequence assembled in contigs is 2.68 billion bp. Assuming that the allele frequency distribution in the YRI is well approximated by that of a simple coalescent model and using an estimate of the population mutation rate of θ = 1.2 per kb for African populations1,2 the expected number of variants with MAF≥0.05 in a sample of 120 chromosomes is 114 = θ E(S MAF≥5% ) L ∑ /1 i i=6 where L is the total length of the sequence3.
    [Show full text]
  • The BCAR1 Locus in Carotid Intima-Media Thickness and Atherosclerosis
    The BCAR1 Locus in Carotid Intima-Media Thickness and Atherosclerosis Freya Boardman-Pretty University College London Thesis submitted for the degree of Doctor of Philosophy 1 Declaration of work I, Freya Boardman-Pretty, confirm that the work presented in this thesis is my own and has been generated by me as the result of my own original research. Where information has been derived from other sources, this has been indicated in the text. My role in the work presented in each chapter is outlined below. In chapter 3 I carried out all bioinformatics analysis, including identification of SNPs in strong LD, analysis of regulatory marks associated with these SNPs using UCSC Genome Browser, HaploReg and ElDorado, and selection of candidate SNPs. I used the Gene-Tissue Expression (GTEx) browser and Gilad/Pritchard eQTL browser to investigate eQTLs. In chapter 4 I was responsible for genotyping the PLIC cohort for the SNP rs4888378. Genotype data and an analysis plan were sent to Danilo Norata and Andrea Baragetti (University of Milan), who carried out the statistical tests that I requested in PLIC and provided test results and the necessary data for the meta-analysis. I carried out the sex-stratified meta-analysis and additional event rate analysis. In chapter 5 I carried out electrophoretic mobility shift assays (EMSAs) on candidate SNPs, multiplex competitor EMSAs and supershift EMSAs. For the luciferase assay, I designed reporter fragments of interest and carried out the cloning experiments to create the four sets of reporter vectors, and carried out the luciferase assays. I also carried out transfection experiments.
    [Show full text]
  • V12a18-Klintworth Pgmkr
    Molecular Vision 2006; 12:159-76 <http://www.molvis.org/molvis/v12/a18/> ©2006 Molecular Vision Received 13 October 2005 | Accepted 8 March 2006 | Published 10 March 2006 CHST6 mutations in North American subjects with macular corneal dystrophy: a comprehensive molecular genetic review Gordon K. Klintworth,1,2 Clayton F. Smith,2 Brandy L. Bowling2 Departments of 1Pathology and 2Ophthalmology, Duke University Medical Center, Durham, NC Purpose: To evaluate mutations in the carbohydrate sulfotransferase-6 (CHST6) gene in American subjects with macular corneal dystrophy (MCD). Methods: We analyzed CHST6 in 57 patients from 31 families with MCD from the United States, 57 carriers (parents or children), and 27 unaffected blood relatives of affected subjects. We compared the observed nucleotide sequences with those found by numerous investigators in other populations with MCD and in controls. Results: In 24 families, the corneal disorder could be explained by mutations in the coding region of CHST6 or in the region upstream of this gene in both the maternal and paternal chromosome. In most instances of MCD a homozygous or heterozygous missense mutation in exon 3 of CHST6 was found. Six cases resulted from a deletion upstream of CHST6. Conclusions: Nucleotide changes within the coding region of CHST6 are predicted to alter the encoded protein signifi- cantly within evolutionary conserved parts of the encoded sulfotransferase. Our findings support the hypothesis that CHST6 mutations are cardinal to the pathogenesis of MCD. Moreover, the observation that some cases of MCD cannot be explained by mutations in CHST6 suggests that MCD may result from other subtle changes in CHST6 or from genetic heterogeneity.
    [Show full text]